Study Summary
This trial is testing a new way to treat lung cancer using genetically-engineered immune cells. The goal is to see if this new treatment is safe and effective.
- Non-Small Cell Lung Cancer
- Lung Adenocarcinoma
- Stage IV Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Lung
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: 3.5 years
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
CISH CRISPR TIL / Phase I Arm
1 of 4
CISH CRISPR TIL / Phase II Arm PD-L1 Negative Cohort
1 of 4
CISH CRISPR TIL / Phase II Arm PD-L1 Positive Cohort
1 of 4
CISH CRISPR TIL plus pembrolizumab / Phase I Arm
1 of 4
Experimental Treatment
70 Total Participants · 4 Treatment Groups
Primary Treatment: CISH CRISPR TIL / Phase I Arm · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 75 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does your research include individuals aged 55 or older?
"This research project is open to individuals aged 18 and over, up until the age of 75." - Anonymous Online Contributor
What criteria must one meet to partake in this clinical examination?
"This clinical trial is recruiting 70 individuals diagnosed with squamous cell carcinoma between the ages of 18 and 75. Applicants must meet a number of criteria, such as having confirmed histologic diagnosis for metastatic NSCLC (PD-L1 negative or positive) that can be treated with anti-PD-1/anti-PD-L1 immunotherapy plus chemotherapy, measurable disease per RECIST version 1.1., ECOG performance status 0 or 1, and more. Patients who have already started first line treatment are also eligible under certain conditions outlined in the requirements list." - Anonymous Online Contributor
Are new participants welcome to join this research endeavor?
"Data hosted on clinicaltrials.gov reveals that, as of September 30th 2022, this particular research trial has ceased its recruitment activities; it was initially posted to the website in November 1st 2022. Fortunately, there are 1946 other medical studies actively enrolling patients at the moment." - Anonymous Online Contributor
What are the key aims of this investigation?
"Intima Bioscience, Inc., the study sponsor has set a 3.5 year timeline to evaluate Phase 1 Safety and Initial Efficacy as their primary objective. Toxicity incidence, overall survival (Kaplan-Meier estimate), and duration of response are all secondary outcomes that will be measured by researchers during this period." - Anonymous Online Contributor